The rapid growth trend experienced in recent years is encouraging Turkish companies to invest in areas under the monopoly of giants. Taking heart from this fact, Has Group of Kayseri decided to embark on the road to molecule production that is currently under the control of international companies. The investment is led by toxicology specialist Dr. Seyfullah Dağıstanlı. The work that has first been initiated 5 years ago within the structure of Hasbiotech will be yielding results upon the commissioning of the site investment. This 20-million Euro investment in Kayseri will lead the way for the discovery of a molecule for Hepatitis C therapy for which no vaccine is currently available worldwide. Dr. Dağıstanlı stated that they are well ahead of their competitors in terms of Hepatitis C molecule production and that they will be capable of producing the vaccine in near future.
Adding that the vaccine has a very high potential, Dr. Dağıstanlı stated: “The market for Hepatitis C vaccine has a magnitude of 35 million doses. We will be unrivalled in this field. Each dose will be sold for 100 dollars. When we multiply this by 5, we have a market of 175 million doses. We are very close to get a result”. Seyfullah Dağıstanlı remarked that they are also working on an anti-cancer drug.